Top

Published in:

01-01-2007 | Education Review

Positron Emission Tomography (PET) and Mammography (PEM) for Breast Cancer: Importance to Surgeons

Author: Lorraine Tafra, MD

Published in: Annals of Surgical Oncology | Issue 1/2007

Excerpt

The unique aspect of positron emission tomography (PET) is the ability of the image to represent the physiology or metabolism of the area of interest as opposed to just its anatomic appearance. Malignancies frequently function at a higher metabolic rate than normal tissue and therefore concentrate [F-18]-fluorodeoxyglucose (FDG, the most commonly used intravenous agent) to a higher degree than normal tissue. …

Minn H, Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15(2):61–6PubMedCrossRef

Hicks RJ, Binns D, Stabin MG. Pattern of uptake and excretion of 18F-FDG in the lactating breast. J Nucl Med 2001; 42:1238–1242PubMed

Nieweg OE, Kim EE, Wong EH, Broussard WF, Singletary SE, Hortobagyi GN, et al. Positron emission tomography with fluorine-18 deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71:3920–3925PubMedCrossRef

Aliaga A, Rousseau JA, Ouellette R, et al. Breast cancer models to study the expression of estrogen receptors with small animal PET imaging. Nucl Med Biol 2004; 31(6):761–70PubMedCrossRef

Schuster DM, Halkar RK. Molecular imaging in breast cancer. Radiol Clin North Am 2004; 42(5):885–908, vi–viiPubMedCrossRef

Krak NC, van der Hoeven JJ, Hoekstra OS, et al. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 2003; 30(5):674–81PubMedCrossRef

Chen X, Moore MO, Lehman CD, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004; 11(10):1115–24PubMedCrossRef

Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35(2):84–99PubMedCrossRef

Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002; 43(4):500–9PubMed

10.

Semple SI, Gilbert FJ, Redpath TW, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 2004; 14(11):2038–45PubMedCrossRef

11.

Wolf G, Aigner RM, Schaffler G, et al. The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake. Breast Cancer Res Treat 2004; 88(3):205–8PubMedCrossRef

12.

Byrne AM, Hill AD, Skehan SJ, et al. Positron emission tomography in the staging and management of breast cancer. Br J Surg 2004; 91(11):1398–409PubMedCrossRef

13.

Lovrics PJ, Chen V, Coates G, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004; 11(9):846–53PubMedCrossRef

14.

Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22(2):277–85PubMedCrossRef

15.

Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J 2005; 11(3):204–9PubMedCrossRef

16.

Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004; 27(4):407–10PubMedCrossRef

17.

Pecking AP, Mechelany-Corone C, Bertrand-Kermorgant F, et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography. Clin Breast Cancer 2001; 2(3):229–34PubMed

18.

Kim SJ, Kim SK, Lee ES, et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004; 15(9):1352–7PubMedCrossRef

19.

Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using F18-fluorodeoxy-d-glucose to predict the pathological response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676–1688PubMed

20.

Danforth DN Jr, Aloj L, Carrasquillo JA, et al. The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002; 75(2):135–46PubMedCrossRef

21.

van Oost FJ, van der Hoeven JJ, Hoekstra OS, et al. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. Eur J Cancer 2004; 40(10):1545–53PubMedCrossRef

22.

Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002; 23(9):857–64PubMedCrossRef

23.

Goerres GW, Michel SC, Fehr MK, et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 2003; 13(7):1635–44PubMedCrossRef

24.

Grahek D, Montravers F, Kerrou K, et al. [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 2004; 31(2):179–88PubMedCrossRef

25.

Walter C, Scheidhauer K, Scharl A, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol 2003; 13(7):1651–6PubMedCrossRef

26.

Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004; 31(7):932–9PubMedCrossRef

27.

Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004; 130(5):266–72PubMedCrossRef

28.

Thompson CJ, Murthy K, Weinberg IN, Mako F. Feasibility study for positron emission mammography. Med Phys 1994; 21(4):529–38PubMedCrossRef

29.

Bergman AM, Thompson CJ, Murthy K, et al. Technique to obtain positron emission mammography images in registration with X-ray mammograms. Med Phys 1998; 25(11):2119–29PubMedCrossRef

30.

Doshi NK, Shao Y, Silverman RW, Cherry SR. Design and evaluation of an LSO PET detector for breast cancer imaging. Med Phys 2000; 27(7):1535–43PubMedCrossRef

31.

Thompson CJ, Murthy K, Aznar M, et al. Preliminary clinical evaluation of an instrument for “positron emission mammography” in the detection of breast cancer. Clin Positron Imaging 1998; 1(4):265PubMedCrossRef

32.

Weinberg I, Majewski S, Weisenberger A, et al. Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med 1996; 23(7):804–6PubMedCrossRef

33.

Qi J, Huesman RH. Scatter correction for positron emission mammography. Phys Med Biol 2002; 47(15):2759–71PubMedCrossRef

34.

Weinberg IN, Beylin D, Zavarzin V, et al. Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat 2005; 4(1):55–60PubMed

35.

Levine EA, Freimanis RI, Perrier ND, et al. Positron emission mammography: initial clinical results. Ann Surg Oncol 2003; 10(1):86–91PubMedCrossRef

36.

Rosen EL, Turkington TG, Soo MS, et al. Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience. Radiology 2005; 234(2):527–34PubMedCrossRef

37.

Tafra L, Cheng Z, Uddo J, et al. Pilot clinical trial of FDG positron emission mammography (PEM) in the surgical management of breast cancer. Ann Surg Oncol 2005; 190(4):628–32

38.

Raylman RR, Majewski S, Weisenberger AG, et al. Positron emission mammography-guided breast biopsy. J Nucl Med 2001; 42(6):960–6PubMed

39.

Smith MF, Raylman RR, Majewski S, Weisenberger AG. Positron emission mammography with tomographic acquisition using dual planar detectors: initial evaluations. Phys Med Biol 2004; 49(11):2437–52PubMedCrossRef

40.

Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36(2):417–28PubMedCrossRef

41.

Chen X, Liu S, Hou Y, et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 2004; 6(5):350–9PubMedCrossRef

42.

Alauddin MM, Shahinian A, Gordon EM, Conti PS. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging 2004; 3(2):76–84PubMedCrossRef

43.

Fei X, Wang JQ, Miller KD, et al. Synthesis of [18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 2004; 31(8):1033–41PubMedCrossRef

44.

Liu CS, Shen YY, Lin CC, et al. Clinical impact of [(18)F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 2002; 32(7):244–7PubMedCrossRef

45.

Min CJ, Tafra L, Verbanac KM. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes. Cancer Res 1998; 58(20):4581–4PubMed

46.

Mannie A, Cheng Z, Sawyer K, Tafra L, Whitworth P, Verbanac K. Use of circulating tumor cells and serum protein markers to monitor breast cancer patients at high risk for recurrent disease. Abstract Book: American Society of Breast Surgeons Annual Meeting, 16–20 March 2005, Los Angeles, CA, USA

47.

Higashi T, Saga T, Ishimori T, et al. What is the most appropriate scan timing for intraoperative detection of malignancy using 18F-FDG-sensitive gamma probe? Preliminary phantom and preoperative patient study. Ann Nucl Med 2004; 18(2):105–14PubMedCrossRef

Title: Positron Emission Tomography (PET) and Mammography (PEM) for Breast Cancer: Importance to Surgeons
Author: Lorraine Tafra, MD
Publication date: 01-01-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9019-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Positron Emission Tomography (PET) and Mammography (PEM) for Breast Cancer: Importance to Surgeons

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2007

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement

Poor Prognosis for Biomarkers

Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma

Risk Factors for Non-Sentinel Lymph Node Metastases in Patients with Breast Cancer. The Outcome of a Multi-institutional Study

Treatment of Advanced Gastrointestinal Stromal Tumor: a Marriage of Targeted Therapy and Surgery?

Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib